Teijin (3401) investor relations material

Group overview and financial performance

• Founded in 1918, with consolidated revenue of ¥873.2 billion and 15,689 employees as of March 2026.

• Adjusted operating income for fiscal 2025 was ¥25.8 billion, with a net loss of ¥88.0 billion and ROE of -22.1%.

• Business spans apparel, specialty materials, healthcare, and new business development, with 52% of revenue from overseas.

• Annual dividend set at ¥50 per share for fiscal 2025.

Business segments and core strengths

• Apparel & Industries integrates manufacturing and trading, with a major business integration planned with Asahi Kasei Advance in October 2026.

• Healthcare & Life Solutions combines home healthcare services, medical devices, and pharmaceuticals, focusing on rare diseases and chronic conditions.

• Materials business leverages advanced resin and battery material technologies, serving diverse industries.

• Specialty materials include global leadership in aramid and carbon fibers, targeting high-value applications like defense and aircraft.

Medium-term management plan (2026–2028)

• Shift from a materials-driven to a customer-driven business model, emphasizing solutions and co-creation with clients.

• Structural reforms target cost reductions, workforce optimization, and focus on high-value segments in aramid, carbon fibers, and pharmaceuticals.

• Financial targets for FY2028: adjusted operating income of ¥60.0 billion and ROE of 8%.

• Growth strategies include horizontal integration, M&A, and expansion in home healthcare and apparel.

• Capital allocation prioritizes disciplined investment in winning areas, stable dividends, and maintaining a strong financial base.